Balyasny Asset Management
OMIC

Balyasny Asset Management’s Singular Genomics Systems, Inc. Common Stock OMIC Stock Holding History

Balyasny Asset Management’s Portfolio OMIC Stock Details OMIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-463
Closed -$11.5K – 2849
2023
Q2 		$11.5K Buy
+463
New +$13.6K ﹤0.01% 2174
2022
Q4 		– Sell
-350
Closed -$26K – 3339
2022
Q3 		$26K Buy
+350
New +$36.6K ﹤0.01% 2549

Other funds holding OMIC

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
QM
QVIDTVM Management The Woodlands, Texas $81.4M AUM 2.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Balyasny Asset Management's OMIC Position: Q3 2023 in Review

Balyasny Asset Management sold out of Singular Genomics Systems, Inc. Common Stock (OMIC) in Q3 2023, closing a stake of 463 shares — an estimated $11.5K sold.

Balyasny Asset Management first reported a position in OMIC in Q3 2022 and held it in 2 quarters. The position peaked at $26K in Q3 2022. 48 funds tracked by Wall St. Rank hold OMIC as of Q3 2023.

  • Balyasny Asset Management reported no remaining Singular Genomics Systems, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Balyasny Asset Management sold 463 Singular Genomics Systems, Inc. Common Stock shares in Q3 2023, an estimated $11.5K.
  • Balyasny Asset Management first reported a position in Singular Genomics Systems, Inc. Common Stock in Q3 2022 and held it in 2 quarters.
  • Balyasny Asset Management's Singular Genomics Systems, Inc. Common Stock position peaked at $26K in Q3 2022.
  • 48 funds tracked by Wall St. Rank held Singular Genomics Systems, Inc. Common Stock as of Q3 2023.

Based on Balyasny Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.